Uremic Pruritus

Also known as: Uremic pruritis / Uraemic pruritus

DrugDrug NameDrug Description
DB00904OndansetronA competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem] Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis [L5221].
DB01041ThalidomideA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
DrugDrug NamePhaseStatusCount
DB00844Nalbuphine1Completed1
DB11938Difelikefalin2Completed1
DB13471Nalfurafine2Terminated1
DB11938Difelikefalin2 / 3Completed1
DB00844Nalbuphine2 / 3Completed2
DB11938Difelikefalin3Active Not Recruiting1
DB11938Difelikefalin3Recruiting3
DB00950Fexofenadine4Unknown Status1
DB00230Pregabalin4Unknown Status2